Alex Parks – CEO and Managing Director – Prominence Energy (ASX:PRM) is an ASX listed oil and gas exploration and development company.
Copyright 2023 – Finance News Network
29 07 2024 - David Flanagan - Managing Director - Arrow Minerals (ASX:AMD) is actively exploring the Simandou North Iron Project (SNIP) in Guinea, West Africa with the intention of discovering and developing a direct shipping grade iron mining operation as soon as possible. The Company intends to take full advantage of the multi-user rail infrastructure currently being developed for the benefit of the Winning Consortium and the SimFer JV due for commissioning from late 2025.
15 Jan 2021 - Famed investor, author and market analyst Jim Rogers discusses the impact of the COVID-19 vaccine rollout, Chinese wine stocks, the bond bubble, why he is bullish on commodities, allegations of currency manipulation and how Aussie investors can get ahead.
31 May 2023 - European Metal Holdings Limited (ASX:EMH) Executive Chairman Keith Coughlan discusses the European demand for lithium and the scale of the company's Cinovec project.
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therapy from the University of Pennsylvania, its recent FDA IND clearance and plans for ongoing growth.
01 Mar 2021 - Nutritional Growth Solutions Limited (ASX:NGS) Chairman Brian Leedman talks about the science behind the company's nutritional supplement formulae for children, which are designed to promote height and weight.
24 Feb 2021 - Shaw and Partners Chief Investment Officer Martin Crabb provides an update on the global economy, US stimulus packages, rising bond yields and their implications for investors.
18 July 2025 - Sovereign Advisors Principal Advisor Zaheer Lalani and Investment Manager Max Riaz emphasise staying rooted in fundamentals and deliberately avoiding media-driven noise and panic
06 Apr 2020 - Cyclopharm (ASX:CYC) CEO & Managing Director, James McBrayer talks about its new drug application with the US FDA for Technegas and applications beyond pulmonary embolism in chronic chronic obstructive pulmonary ( COPD ) and asthma.